The life science and medical device industries are undergoing rapid evolution, with Industry 4.0 and AI technologies gaining extensive penetration. Efficient transformation of innovative achievements and stable mass production of precision products have become the key to corporate competitiveness.
Against the rapid advancement of organoid technology and precision medicine, organoids are finding expanding applications spanning new drug development, tumor drug sensitivity screening and disease model establishment. They deliver critical support for biomedical innovation and personalized treatment. Nevertheless, the generation, culture and testing of organoids heavily rely on manual operation.